Showing results (221-230 of 293) with videos related to
Sort By:
Pageof 30
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.Frontiers in Medicine|June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination TrialsChanning J Paller, Erich P Huang, Thomas Luechtefeld, et al.Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Cediranib for metastatic alveolar soft part sarcomaShivaani Kummar, Deborah Allen, Anne Monks, et al.American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.The Journal of Biological Chemistry|April 6, 2016
Hypercapnia Suppresses the HIF-dependent Adaptive Response to HypoxiaAndrew C Selfridge, Miguel A S Cavadas, Carsten C Scholz, et al.Physiological Reviews|July 16, 2025
Sensing molecular carbon dioxide: a translational focus for respiratory diseaseIstván Vadász, Eoin P Cummins, Deborah H Brotherton, et al.Pageof 30